Prelude Therapeutics Incorporated is a precision oncology company focused on drug discovery and development of novel cancer medicines. The company develops kinase inhibitors, targeted protein degraders, and antibody-drug conjugates. Key programs include PRT12396, a mutant-selective JAK2V617F inhibitor for myeloproliferative neoplasms, and a KAT6A selective degrader for ER+ breast cancer. Prelude has partnered with Incyte Corporation on JAK2V617F and with AbCellera Biologics on degrader-payload antibody programs.
Q2 FY2026 — expected 2026-09-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-10 | 2025-12-31 | 0001193125-26-099428 | EDGAR | 84K words |
| 2025-03-10 | 2024-12-31 | 0000950170-25-035921 | EDGAR | 83K words |
| 2024-02-15 | 2023-12-31 | 0000950170-24-016016 | EDGAR | 79K words |
| 2023-03-15 | 2022-12-31 | 0000950170-23-007989 | EDGAR | — |
| 2022-03-17 | 2021-12-31 | 0001564590-22-010723 | EDGAR | — |
| 2021-03-16 | 2020-12-31 | 0001564590-21-013330 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-11 | 2026-06-30 | 0001193125-26-343475 | EDGAR | 20K words |
| 2025-11-12 | 2025-09-30 | 0001193125-25-275887 | EDGAR | 21K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-108417 | EDGAR | 20K words |
| 2025-05-06 | 2025-03-31 | 0000950170-25-064566 | EDGAR | 18K words |
| 2024-11-06 | 2024-09-30 | 0000950170-24-122377 | EDGAR | 22K words |
| 2024-08-12 | 2024-06-30 | 0000950170-24-095065 | EDGAR | 21K words |
| 2024-05-07 | 2024-03-31 | 0000950170-24-053940 | EDGAR | 17K words |
| 2023-11-01 | 2023-09-30 | 0000950170-23-057523 | EDGAR | 19K words |
| 2023-08-03 | 2023-06-30 | 0000950170-23-037611 | EDGAR | 18K words |
| 2023-05-08 | 2023-03-31 | 0000950170-23-018478 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0000950170-22-024732 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001564590-22-028596 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-10 | 0001193125-26-387232 | EDGAR | 4K words |
| 2026-08-11 | 0001193125-26-343469 | EDGAR | 3K words |
| 2026-03-12 | 0001193125-26-104204 | EDGAR | 1K words |
| 2026-03-10 | 0001193125-26-099424 | EDGAR | 3K words |
| 2026-02-03 | 0001193125-26-034564 | EDGAR | 1K words |
| 2026-01-09 | 0001193125-26-008280 | EDGAR | 3K words |
| 2025-11-12 | 0001193125-25-275871 | EDGAR | 3K words |
| 2025-11-04 | 0000929638-25-004115 | EDGAR | 2K words |
| 2025-10-17 | 0001193125-25-241968 | EDGAR | 1K words |
| 2025-09-19 | 0001193125-25-208187 | EDGAR | 1K words |
107 total filings indexed. 79 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001678660 |
| Ticker | PRLD |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.preludetx.com |
| Listed | 2020-09-25 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/PRLD (~200 tokens, structured JSON with cryptographic provenance)